Shanghai Ark Biopharmaceutical Co., Ltd.

上海爱科百发生物医药技术股份有限公司

Biopharmaceutical company developing therapeutics for respiratory and pediatric diseases in China, with a pipeline including an RSV antiviral (ziresovir) at NDA stage, an RSV-prevention mAb, an IPF drug, and an approved ADHD drug.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Losses and path to profitability
• Cash burn and runway
• Investments and fair-value assets
• Non-recurring gains and losses
• Chapter 18A biotech
• Sanctioned countries and export controls